Company intelligence / Profile preview
Tricision Biotherapeutics
Beijing, Beijing, Chinatricisionbio.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Tricision Biotherapeutics has shown promising results in early-phase clinical studies, with a personalized dendritic cell mRNA vaccine (TriVac-modified) achieving 69 months of progression-free survival in a glioblastoma patient and demonstrating safety with no significant immunotherapy-related adverse events
- Therapeutic areas
- OncologyInfectious DiseasesRare DiseasesImmunology
- Modalities
- mRNA-based drugsCell therapyProphylactic vaccineTherapeutic vaccine
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
03
Partnerships
CR Biopharm (joint development of mRNA-dendritic cell vaccine)Mingdu Zhiyun (collaboration for COVID-19 pipeline)Duke University/Johns Hopkins University (licensed TriVac technology via TriVac Inc.)
Beyond the preview
Go deeper on Tricision Biotherapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Tricision Biotherapeutics.